Out of interest..... Ipsen S.A. operates as a pharmaceutical...

Out of interest.....
Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of gro...

About Ipsen
Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014.
Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 30
countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating
diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urologyoncology.
Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies
improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrine tumors.
Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of
partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides
and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis, France;
Slough/Oxford, UK; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million, representing
about 15% of Group sales. The Group has more than 4,500 employees worldwide. Ipsen’s shares are
traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the
“Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a
Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter​

market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
-
-Sales in the Major Western European countries represented 39.1% of total
Group sales in the first quarter 2015, compared to 42.2% the previous year.
-“Following the

improved sales expectations and the savings resulting from discontinuation of all developments with​

tasquinimod in prostate cancer, we raise our sales and profitability guidance for 2015.”
= spare coin.